Role of glycoproteins in hepatic lipid metabolism: emerging diagnostic markers and therapeutic targets

糖蛋白在肝脏脂质代谢中的作用:新兴的诊断标志物和治疗靶点

阅读:2

Abstract

The liver is an important metabolic organ in the human body, and abnormal hepatic lipid metabolism may lead to a variety of diseases such as metabolic dysfunction-associated fatty liver disease, cirrhosis, and hepatocellular carcinoma. These diseases are often closely associated with chronic diseases, including obesity, hypertension, high cholesterol and diabetes, and have become major factors increasing the global disease burden. Currently, the diagnosis of diseases related to hepatic lipid metabolism relies mainly on imaging findings and serologic markers. In terms of treatment, lifestyle interventions such as dietary changes and increased exercise remain the mainstay of the fight against the diseases. However, effective therapies to control the progression of these diseases are still lacking. Glycoproteins are complex biomolecules consisting of sugar chains and proteins bound covalently, which are widely found in cell membranes and secretory fluids. In recent years, researchers have found that glycoproteins have potential application value in the diagnosis and treatment of diseases related to hepatic lipid metabolism. But there are currently no articles summarizing and analyzing the pathways and mechanisms involved. This review provides an overview of the progress of research on glycoproteins involved in diseases related to hepatic lipid metabolism as well as new insights into glycoproteins as potential diagnostic markers and therapeutic targets for lipid metabolism diseases.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。